GIB · GLOBEINTELREPORT.COM
Trump Administration agreements, negotiating leverage, tariff measures, retaliation, and measured outcomes
Follow how trade measures affect household costs, production, investment and the federal ledger.
Open the economic assessment →Current status · Aug. 23, 2026
Official actions and partner positions are separated from GIB assessment. Rates are headline measures; exclusions and tariff schedules control actual product treatment.
Trade negotiations dashboard
GIB assessment: Completed agreements generally pair continuing U.S. tariff protection with foreign market opening, purchase, or security commitments. Canada and Mexico remain the highest-consequence tests because integrated North American supply chains make pressure, disruption, and retaliation unusually immediate.
Remove barriers affecting U.S. alcohol, dairy, and autos; improve U.S.-content treatment; obtain wider economic-security alignment.
Targeted 50% U.S. duties are active. Canada ended the talks and announced matching retaliation after each side accused the other of changing or abandoning the terms.
Negotiation restart or Canada’s September 8 retaliation.
Tighten outcomes on autos, metals, labor, agriculture, electronic payments, and economic security before the joint-review decision.
A third bilateral negotiating round convened in Mexico City in July; USTR has not posted a final joint-review outcome.
Published next steps, another round, or a formal USMCA review decision.
Expand U.S. export access and purchase commitments while linking tariff relief to energy and economic-security cooperation.
The February deal removed an additional 25% U.S. tariff after India’s commitment to stop purchasing Russian oil; implementation outcomes remain the next test.
Verified tariff-schedule implementation, purchases, and market-access results.
Remove tariff and non-tariff barriers and strengthen resilient high-technology supply chains.
The Agreement on Reciprocal Trade was signed February 12 with a published text and tariff schedule.
Implementation milestones and measured U.S. export and supply-chain outcomes.
Open Indonesian markets while retaining a protective U.S. tariff and defined zero-rate exceptions.
The finalized agreement retains a 19% U.S. reciprocal tariff on most Indonesian imports, with identified products at 0%.
Implementation, compliance, purchase commitments, and realized U.S. export gains.
Secure U.S.-goods purchases, remove barriers, and deepen a strategic Middle East economic partnership.
The Agreement on Reciprocal Trade was signed July 21 with agreement text and a tariff schedule published by USTR.
Entry into operation and independently measured market-access results.
Tariff negotiations dashboard
GIB assessment: The administration is using tariffs simultaneously as bargaining leverage, sector protection, revenue policy, and a conditional incentive for onshoring. Success should be measured through signed concessions, implementation, domestic capacity, employment, government revenue, and household or business prices—not the announced rate alone.
Targeted Canadian alcohol, dairy, vehicle, and other listed goods; stated exemptions include energy, potash, critical minerals, fish, and goods already covered by Section 232.
Direct leverage for removal of alleged Canadian discrimination; the three-day pause expired without a deal.
Exclusions, a restart, Canadian retaliation, or a superseding agreement.
50% on core covered metals, 25% on derivatives, and a temporary 15% rate on certain industrial machinery and power equipment.
Protect domestic capacity and create partner leverage; country arrangements and product treatment can modify exposure.
Partner-specific relief, exclusions, domestic output, investment, employment, and downstream cost evidence.
Certain advanced chips, including the NVIDIA H200 and AMD MI325X, with exclusions tied to U.S. technology-supply-chain buildout.
Encourage domestic capacity and negotiate supply-chain commitments; a broader second phase remains pending.
Second-phase rate and scope, offset rules, and verified domestic investment or production.
Patented drugs and ingredients, with different phase-in periods for larger and smaller companies.
Companies with executed or active agreements on U.S. MFN pricing and onshoring can qualify for zero-tariff treatment.
Company agreements, effective-date treatment, import pricing, U.S. investment, and medicine-cost effects.
15% for listed allied sources and 10% for the United Kingdom, conditioned on qualifying hardware, software, technology, and origin requirements.
Use differentiated tariff treatment to favor trusted supply chains and domestic production.
Origin enforcement, partner compliance, U.S. capacity, and price or availability effects.